---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011465"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:04:36.492512+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Q2 net loss $0.60/shr; cash $190.5M; Phase 3 SAPPHIRE data on track Q4 2024

## Summary
- Net loss $58.5M ($0.60/shr) vs $37.9M ($0.47/shr) in Q2 2023; no revenue.
- Cash $190.5M; expected to fund operations into H2 2025.
- Phase 3 SAPPHIRE topline data for apitegromab in SMA expected Q4 2024; commercial launch targeted 2025 if successful.
- Phase 2 EMBRAZE (apitegromab + GLP-1 in obesity) now expects topline data Q2 2025; IND for SRK-439 planned in 2025.
- Long-term TOPAZ data: 48-month mean HFMSE improvement 5.3 points (2-21 yrs); >90% patient retention.

## SEC filing metadata
- accession: 0001558370-24-011465
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837024011465/0001558370-24-011465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837024011465/srrk-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011465
- JSON: https://secwatch.observer/filing/0001558370-24-011465.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.